Wall Street equity research analysts covering Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) maintain a general consensus rating of Buy. Financial institutions and biotechnology sector analysts have established positive twelve-month price targets—averaging around $5.00 to $6.60 per share—reflecting clinical developments surrounding its lead drug candidates, regulatory pathway updates for dry eye disease treatments, and strategic biopharmaceutical partnerships.